Target
|
RA-FFF
|
RA
|
IMRT
|
p value
|
p
1
|
p
2
|
p
3
|
---|
PTV70
| | | | | | | |
D99%(Gy)
|
68.52 ± 0.46
|
68.69 ± 0.59
|
69.06 ± 0.22
|
0.122
|
—
|
—
|
—
|
D1%(Gy)
|
75.40 ± 1.32
|
74.08 ± 1.12
|
74.30 ± 0.62
|
0.007
|
0.005
|
0.028
|
0.878
|
Dmean(Gy)
|
72.80 ± 0.72
|
72.15 ± 0.68
|
71.95 ± 0.21
|
0.007
|
0.005
|
0.012
|
0.333
|
V70(%)
|
95.00 ± 0.00
|
95.00 ± 0.00
|
95.00 ± 0.00
|
—
|
—
|
—
|
—
|
CI
|
0.486 ± 0.213
|
0.609 ± 0.199
|
0.519 ± 0.220
|
0.014
|
0.007
|
0.445
|
0.037
|
HI
|
0.087 ± 0.023
|
0.067 ± 0.021
|
0.069 ± 0.011
|
0.008
|
0.005
|
0.028
|
0.646
|
PTV66
| | | | | | | |
D99%(Gy)
|
65.26 ± 0.99
|
65.19 ± 0.98
|
66.07 ± 1.09
|
0.121
|
—
|
—
|
—
|
D1%(Gy)
|
72.74 ± 1.58
|
71.34 ± 1.46
|
72.25 ± 1.53
|
0.008
|
0.008
|
0.314
|
0.799
|
Dmean(Gy)
|
69.67 ± 0.99
|
68.90 ± 0.85
|
70.18 ± 1.18
|
0.001
|
0.008
|
0.155
|
0.008
|
V66(%)
|
97.65 ± 1.28
|
97.53 ± 1.37
|
99.08 ± 0.60
|
0.050
|
—
|
—
|
—
|
CI
|
0.209 ± 0.074
|
0.244 ± 0.074
|
0.226 ± 0.083
|
0.169
|
—
|
—
|
—
|
HI
|
0.108 ± 0.054
|
0.088 ± 0.052
|
0.080 ± 0.048
|
0.001
|
0.008
|
0.008
|
0.123
|
PTV60
| | | | | | | |
D99%(Gy)
|
57.97 ± 0.84
|
57.88 ± 0.77
|
58.54 ± 0.71
|
0.006
|
0.508
|
0.009
|
0.009
|
D1%(Gy)
|
74.31 ± 1.08
|
73.38 ± 1.02
|
73.30 ± 0.61
|
0.025
|
0.009
|
0.022
|
0.799
|
Dmean(Gy)
|
66.23 ± 0.93
|
65.55 ± 1.08
|
66.47 ± 0.91
|
0.001
|
0.005
|
0.333
|
0.005
|
V60(%)
|
96.36 ± 0.87
|
96.13 ± 0.95
|
97.88 ± 0.44
|
0.002
|
0.445
|
0.005
|
0.007
|
CI
|
0.793 ± 0.025
|
0.811 ± 0.023
|
0.813 ± 0.025
|
0.002
|
0.005
|
0.022
|
0.575
|
HI
|
0.230 ± 0.040
|
0.217 ± 0.044
|
0.199 ± 0.038
|
0.001
|
0.047
|
0.005
|
0.005
|
- Abbreviations: CI = conformity index; HI = homogeneity index; D
99%
= dose received by 99% of the volume; p1 = Wilcoxon test p value between RA-FFF and RA plans; p2 = Wilcoxon test p value between RA-FFF and IMRT plans; p3 = Wilcoxon test p value between RA and IMRT plans. Other abbreviations as in Table 1.